Zdrowie i gospodarka · 27/11/2013
FDA Reopens Comment Period for Bioequivalence Guidance
The FDA is reopening the comment period for its draft guidance on bioequivalence recommendations for Fluticasone Propionate and Salmeterol Xinafoate, originally published in 2013, due to technical issues with the online comment submission process.